Inuver

Beclometasone dipropionate / Formoterol fumarate, the active ingredient in Inuver, is an inhaled corticosteroid/long‑acting β2‑agonist combination presented as an inhalation product for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adult patients by reducing airway inflammation and providing sustained bronchodilation. The formulation is designed for delivery via a metered‑dose inhaler, ensuring rapid deposition in the lower respiratory tract.

GNH USA supplies Inuver as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality and regulatory compliance.

Inuver combines an inhaled corticosteroid with a long‑acting β2‑agonist to manage chronic airway diseases.

Asthma: improves symptom control and reduces the frequency of exacerbations COPD: enhances lung function and decreases breathlessness during daily activities Bronchial hyperresponsiveness: provides maintenance bronchodilation and anti‑inflammatory effect

Inhalation of Inuver may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Throat irritation or soreness - Oral candidiasis (thrush) - Headache

Serious or Rare Side Effects: - Paradoxical bronchospasm - Severe allergic reaction (anaphylaxis) - Adrenal suppression with prolonged high‑dose use

Before using Inuver, patients and clinicians should consider several safety measures.

Assess asthma or COPD control before initiating therapy: ensure patient is stable Monitor for oral thrush: advise rinsing mouth after each inhalation Use the lowest effective dose to maintain symptom control Avoid abrupt discontinuation: taper under medical supervision Caution in patients with cardiovascular disease: monitor heart rate and blood pressure Store at ambient temperature: keep in original container, protect from moisture and heat

Inuver may interact with other medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase systemic exposure to both components - Diuretics (e.g., furosemide): may potentiate hypokalemia when combined with formoterol

Moderate Interactions (Monitor Closely): - Diabetes medications: β2‑agonist may raise blood glucose levels - Theophylline: additive stimulant effect on the cardiovascular system - Vaccines (live attenuated): inhaled steroids may reduce immune response